-
1
-
-
0008690916
-
Cortisone in ulcerative colitis; final report on a therapeutic trial
-
Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 4947: 1041-8.
-
(1955)
Br Med J
, vol.4947
, pp. 1041-1048
-
-
Truelove, S.C.1
Witts, L.J.2
-
2
-
-
0025994645
-
Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987
-
Langholz E, Munkholm P, Nielsen OH et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26: 1247-56.
-
(1991)
Scand J Gastroenterol
, vol.26
, pp. 1247-1256
-
-
Langholz, E.1
Munkholm, P.2
Nielsen, O.H.3
-
3
-
-
3843109109
-
Ulcerative colitis practice guidelines in adults (update)
-
American College of Gastroenterology, Practice Parameters Committee
-
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update). American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85.
-
(2004)
Am J Gastroenterol
, vol.99
, pp. 1371-1385
-
-
Kornbluth, A.1
Sachar, D.B.2
-
4
-
-
2342445762
-
Management of inflammatory bowel disease
-
Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J 2004; 80: 206-13.
-
(2004)
Postgrad Med J
, vol.80
, pp. 206-213
-
-
Nayar, M.1
Rhodes, J.M.2
-
5
-
-
4344602852
-
Guidelines for the management of inflammatory bowel disease in adults
-
Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: V1-16.
-
(2004)
Gut
, vol.53
-
-
Carter, M.J.1
Lobo, A.J.2
Travis, S.P.3
-
6
-
-
84980093255
-
The treatment of 124 cases of ulcerative colitis with salazapyrine and attempts at desensitization in cases of hypersensitivity to sulfa
-
Svartz N. The treatment of 124 cases of ulcerative colitis with salazapyrine and attempts at desensitization in cases of hypersensitivity to sulfa. Acta Med Scand 1948; 139: 465-72.
-
(1948)
Acta Med Scand
, vol.139
, pp. 465-472
-
-
Svartz, N.1
-
7
-
-
0030827118
-
A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
-
Safdi M, DeMicco M, Sninsky C et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71.
-
(1997)
Am J Gastroenterol
, vol.92
, pp. 1867-1871
-
-
Safdi, M.1
DeMicco, M.2
Sninsky, C.3
-
8
-
-
21044433011
-
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: A randomised, double blind, placebo controlled study
-
Marteau P, Probert CS, Lindgren S et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: A randomised, double blind, placebo controlled study. Gut 2005; 54: 960-5.
-
(2005)
Gut
, vol.54
, pp. 960-965
-
-
Marteau, P.1
Probert, C.S.2
Lindgren, S.3
-
9
-
-
0034061366
-
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis
-
Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-76.
-
(2000)
Am J Gastroenterol
, vol.95
, pp. 1263-1276
-
-
Cohen, R.D.1
Woseth, D.M.2
Thisted, R.A.3
Hanauer, S.B.4
-
10
-
-
0023521441
-
Coated oral 5-aminosalicyclic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
-
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicyclic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
-
(1987)
N Engl J Med
, vol.317
, pp. 1625-1629
-
-
Schroeder, K.W.1
Tremaine, W.J.2
Ilstrup, D.M.3
-
12
-
-
8844258136
-
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease
-
Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Ad Drug Deliv Rev 2005; 57: 267-79.
-
(2005)
Ad Drug Deliv Rev
, vol.57
, pp. 267-279
-
-
Klotz, U.1
Schwab, M.2
-
14
-
-
33645472846
-
-
Salazopyrin Summary of Product Characteristics (SmPC)
-
Salazopyrin Summary of Product Characteristics (SmPC). 2004.
-
(2004)
-
-
-
15
-
-
33645464770
-
-
Asacol® Summary of Product Characteristics (SmPC)
-
Asacol® Summary of Product Characteristics (SmPC). 2003.
-
(2003)
-
-
-
16
-
-
33645462936
-
An analysis of factors that influence selection of the induction dose of delayed-release oral mesalamine (Asacol) in ulcerative colitis in the community setting
-
Poster and Abstract, R.0469. [WWW document] URL (accessed February 2005)
-
Sands BE, Bloomfeld RS, Sandborn WJ et al. An analysis of factors that influence selection of the induction dose of delayed-release oral mesalamine (Asacol) in ulcerative colitis in the community setting. World Congress of Gastroenterology 2005. Poster and Abstract, R.0469. [WWW document] URL http://www.pulsus.com/search.cfm. (accessed February 2005).
-
(2005)
World Congress of Gastroenterology
-
-
Sands, B.E.1
Bloomfeld, R.S.2
Sandborn, W.J.3
-
17
-
-
25144473178
-
Delayed-release oral mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: Combined analysis of two randomized, double-blind, controlled trials
-
Hanauer SB, Sandborn WJ, Kornbluth A, Hardi R, Regalli G, Yeh C. Delayed-release oral mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: Combined analysis of two randomized, double-blind, controlled trials. Gastroenterology 2005; 128: A74-A75.
-
(2005)
Gastroenterology
, vol.128
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Kornbluth, A.3
Hardi, R.4
Regalli, G.5
Yeh, C.6
-
18
-
-
33645466493
-
Delayed-release oral mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: Combined efficacy analysis of two randomized, double-blind, controlled trials
-
Poster and Abstract, R.0470. [WWW document] URL (accessed February 2005)
-
Hanauer SB, Sandborn WJ, Kornbluth A, Hardi R, Regalli G, Yeh C. Delayed-release oral mesalamine 4.8g/day (800mg tablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: combined efficacy analysis of two randomized, double-blind, controlled trials. World Congress of Gastroenterology. Poster and Abstract, R.0470. [WWW document] URL http://www.pulsus.com/search.cfm. (accessed February 2005).
-
World Congress of Gastroenterology
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Kornbluth, A.3
Hardi, R.4
Regalli, G.5
Yeh, C.6
-
19
-
-
33645462863
-
Combined subgroup analyses of two randomized, double-blind, controlled trials: Delayed-release oral mesalamine 4.8g/day (800 mg tablet) versus 2.4g/day (400 mg tablet) for treatment of moderately active ulcerative colitis: Combined efficacy analysis of two randomized, double-blind, controlled trials
-
Poster and Abstract, R.0468. [WWW document] URL (accessed February 2005)
-
Sandborn WJ, Hanauer SB, Katz S et al. Combined subgroup analyses of two randomized, double-blind, controlled trials: Delayed-release oral mesalamine 4.8g/day (800 mg tablet) versus 2.4g/day (400 mg tablet) for treatment of moderately active ulcerative colitis: Combined efficacy analysis of two randomized, double-blind, controlled trials. World Congress of Gastroenterology. Poster and Abstract, R.0468. [WWW document] URL http://www.pulsus.com/search.cfm. (accessed February 2005).
-
World Congress of Gastroenterology
-
-
Sandborn, W.J.1
Hanauer, S.B.2
Katz, S.3
-
20
-
-
33645466728
-
Safety of delayed-release oral mesalamine 4.8g/day (800mg tablet) compared to 2.4g/day (400mg tablet) for treatment of active ulcerative colitis: Analysis of combined data from two randomized, double-blind, controlled trials
-
Poster and Abstract, R.0471. [WWW document] URL (accessed February 2005)
-
Hanauer SB, Loftus EV, Binion DG, Gordon GL, Smith-Hall N, Law L. Safety of delayed-release oral mesalamine 4.8g/day (800mg tablet) compared to 2.4g/day (400mg tablet) for treatment of active ulcerative colitis: analysis of combined data from two randomized, double-blind, controlled trials. World Congress of Gastroenterology. Poster and Abstract, R.0471. [WWW document] URL http://www.pulsus.com/search.cfm. (accessed February 2005).
-
World Congress of Gastroenterology
-
-
Hanauer, S.B.1
Loftus, E.V.2
Binion, D.G.3
Gordon, G.L.4
Smith-Hall, N.5
Law, L.6
|